Z
Zeynep Yesim Kucuk
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 16
Citations - 1201
Zeynep Yesim Kucuk is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 13, co-authored 16 publications receiving 869 citations. Previous affiliations of Zeynep Yesim Kucuk include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Tanya I. Coulter,Anita Chandra,Chris M. Bacon,Judith Babar,James Curtis,Nicholas Screaton,John R. Goodlad,George Farmer,Cathal Laurence Steele,Timothy Ronan Leahy,Rainer Doffinger,Helen Baxendale,Jolanta Bernatoniene,J. David M. Edgar,Hilary Longhurst,Stephan Ehl,Carsten Speckmann,Bodo Grimbacher,Anna Sediva,Tomas Milota,Saul N. Faust,Anthony P. Williams,Grant Hayman,Zeynep Yesim Kucuk,Rosie Hague,Paul French,Richard Brooker,Peter Forsyth,Richard Herriot,Caterina Cancrini,Paolo Palma,Paola Ariganello,Niall Conlon,Conleth Feighery,Patrick J. Gavin,Alison Jones,Kohsuke Imai,Mohammad A. A. Ibrahim,Gašper Markelj,Mario Abinun,Frédéric Rieux-Laucat,Sylvain Latour,Isabelle Pellier,Alain Fischer,Fabien Touzot,Jean-Laurent Casanova,Anne Durandy,Siobhan O. Burns,Sinisa Savic,Dinakantha S. Kumararatne,Despina Moshous,Sven Kracker,Bart Vanhaesebroeck,Klaus Okkenhaug,Capucine Picard,Sergey Nejentsev,Alison M. Condliffe,Andrew J. Cant +57 more
TL;DR: The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease and clinical trials of selective PI3K&dgr; inhibitors offer new prospects for APDS treatment.
Journal ArticleDOI
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Charlotte Schwab,Annemarie Gabrysch,Peter Olbrich,Virginia Patiño,Klaus Warnatz,Daniel Wolff,Akihiro Hoshino,Masao Kobayashi,Kohsuke Imai,Masatoshi Takagi,Ingunn Dybedal,Jamanda A. Haddock,David M. Sansom,José Manuel Lucena,Maximilian Seidl,Annette Schmitt-Graeff,Veronika Reiser,Florian Emmerich,Natalie Frede,Alla Bulashevska,Ulrich Salzer,Desirée Schubert,Seiichi Hayakawa,Satoshi Okada,Maria Kanariou,Zeynep Yesim Kucuk,Hugo Chapdelaine,Lenka Petruzelkova,Zdenek Sumnik,Anna Sediva,Mary Slatter,Peter D. Arkwright,Andrew J. Cant,Hanns-Martin Lorenz,Thomas Giese,Vassilios Lougaris,Alessandro Plebani,Christina Price,Kathleen E. Sullivan,Michel Moutschen,Jiri Litzman,Tomáš Freiberger,Frank L. van de Veerdonk,Mike Recher,Michael H. Albert,Fabian Hauck,Suranjith L. Seneviratne,Jana Pachlopnik Schmid,Antonios G.A. Kolios,Gary Unglik,Christian Klemann,Christian Klemann,Carsten Speckmann,Stephan Ehl,Alan M. Leichtner,Richard S. Blumberg,Andre Franke,Scott B. Snapper,Sebastian Zeissig,Sebastian Zeissig,Sebastian Zeissig,Charlotte Cunningham-Rundles,Lisa Giulino-Roth,Olivier Elemento,Gregor Dückers,Tim Niehues,Eva Fronkova,Veronika Kanderova,Craig D. Platt,Janet Chou,Talal A. Chatila,Raif S. Geha,Elizabeth M. McDermott,Su Bunn,Monika Kurzai,Ansgar Schulz,Laia Alsina,Ferran Casals,Angela Deyà-Martínez,Sophie Hambleton,Hirokazu Kanegane,Kjetil Taskén,Olaf Neth,Bodo Grimbacher,Bodo Grimbacher +84 more
TL;DR: The penetrance, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers, finding affected mutation carriers with CTLA‐4 insufficiency can present in any medical specialty.
Journal ArticleDOI
Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study
Federica Barzaghi,Laura C. Amaya Hernandez,Benedicte Neven,Silvia Ricci,Zeynep Yesim Kucuk,Jack J. Bleesing,Zohreh Nademi,Mary Slatter,Erlinda R. Ulloa,Anna Shcherbina,Anna Roppelt,Austen Worth,Juliana Silva,Alessandro Aiuti,Luis Murguia-Favela,Carsten Speckmann,Magda Carneiro-Sampaio,Juliana Folloni Fernandes,Safa Baris,Ahmet Ozen,Elif Karakoc-Aydiner,Ayca Kiykim,Ansgar Schulz,Sandra Steinmann,Lucia Dora Notarangelo,Eleonora Gambineri,Paolo Lionetti,William T. Shearer,Lisa R. Forbes,Caridad Martinez,Despina Moshous,Stéphane Blanche,Alain Fisher,Frank M. Ruemmele,Come Tissandier,Marie Ouachée-Chardin,Frédéric Rieux-Laucat,Marina Cavazzana,Waseem Qasim,Barbarella Lucarelli,Michael H. Albert,Ichiro Kobayashi,Laura C. Alonso,Cristina Díaz de Heredia,Hirokazu Kanegane,Anita Lawitschka,Jong Jin Seo,Marta González-Vicent,Miguel Angel Diaz,Rakesh K. Goyal,Martin Sauer,Akif Yesilipek,Minsoo Kim,Yesim Yilmaz-Demirdag,Monica Bhatia,Julie Khlevner,Erick J. Richmond Padilla,Silvana Martino,Davide Montin,Olaf Neth,Agueda Molinos-Quintana,Justo Valverde-Fernandez,Arnon Broides,Vered Pinsk,Antje Ballauf,Filomeen Haerynck,Victoria Bordon,Catharina Dhooge,Maria Laura Garcia-Lloret,Robbert G. M. Bredius,Krzysztof Kałwak,Elie Haddad,Markus G. Seidel,Gregor Dückers,Sung-Yun Pai,Sung-Yun Pai,Christopher C. Dvorak,Stephan Ehl,Franco Locatelli,Frederick D. Goldman,Andrew R. Gennery,M.J. Cowan,Maria Grazia Roncarolo,Rosa Bacchetta +83 more
TL;DR: Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long‐term disease‐free survival, and when performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.
Journal ArticleDOI
Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations.
Charline Miot,Kohsuke Imai,Chihaya Imai,Anthony J. Mancini,Anthony J. Mancini,Zeynep Yesim Kucuk,Tokomki Kawai,Ryuta Nishikomori,Etsuro Ito,Isabelle Pellier,Sophie Dupuis Girod,Jérémie Rosain,Shinya Sasaki,Shanmuganathan Chandrakasan,Shanmuganathan Chandrakasan,Jana Pachlopnik Schmid,Tsubasa Okano,Estelle Colin,Alberto Olaya-Vargas,Marco Antonio Yamazaki-Nakashimada,Waseem Qasim,Sara Espinosa Padilla,Andrea M. Jones,Alfons Krol,Nyree Cole,Stephen Jolles,Jack J. Bleesing,Thomas Vraetz,Andrew R. Gennery,Mario Abinun,Mario Abinun,Tayfun Güngör,Beatriz Tavares Costa-Carvalho,Antonio Condino-Neto,Paul Veys,Steven M. Holland,Gulbu Uzel,Despina Moshous,Benedicte Neven,Stéphane Blanche,Stephan Ehl,Rainer Doffinger,Smita Y. Patel,Anne Puel,Anne Puel,Anne Puel,Jacinta Bustamante,Erwin W. Gelfand,Jean-Laurent Casanova,Jordan S. Orange,Capucine Picard +50 more
TL;DR: Overall, HSCT can cure most clinical features of patients with a variety of IKBKG mutations, and the underlying mutation does not appear to have any influence, as patients with the same mutation had different outcomes.
Journal ArticleDOI
Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders
James Slack,Michael H. Albert,Dmitry Balashov,Bernd H. Belohradsky,Alice Bertaina,Jack J. Bleesing,Claire Booth,Jochen Buechner,Rebecca H. Buckley,Marie Ouachée-Chardin,E.V. Deripapa,Katarzyna Drabko,Mary Eapen,Tobias Feuchtinger,Andrea Finocchi,H. Bobby Gaspar,Sujal Ghosh,Alfred P. Gillio,Luis Ignacio Gonzalez-Granado,Eyal Grunebaum,Tayfun Güngör,Carsten Heilmann,Merja Helminen,Kohei Higuchi,Kohsuke Imai,Krzysztof Kałwak,Nubuo Kanazawa,Gulsun Karasu,Zeynep Yesim Kucuk,Alexandra Laberko,Andrzej Lange,Nizar Mahlaoui,Roland Meisel,Despina Moshous,Hideki Muramatsu,Suhag Parikh,Srdjan Pasic,Irene Schmid,Catharina Schuetz,Ansgar Schulz,Kirk R. Schultz,Peter J. Shaw,Mary Slatter,Karl-Walter Sykora,Shinobu Tamura,Mervi Taskinen,Angela Wawer,Beata Wolska-Kuśnierz,Morton J. Cowan,Alain Fischer,Andrew R. Gennery,Marrow Transplantation +51 more
TL;DR: RIC HCT resolves DNA repair disorder–associated immunodeficiency and long‐term follow‐up is required for secondary malignancy surveillance.